Pfizer Inc. has completed enrolling children aged 12 to 15 in a COVID-19 vaccine study, the drug maker confirmed Friday. 

Pfizer said the Phase 3 clinical trial began in late July 2020 and completed enrollment of 46,331 participants in January, including over 2,200 participants aged 12-15. The company also plans to study the vaccine in pregnant women, among other populations. 

Vaccines from Pfizer and Moderna Inc. are not currently available for use in children due to a lack of studies. The Food and Drug Administration last month authorized emergency use of the vaccine for individuals age 16 and older. 

Related News Articles

Headline
In a study of symptomatic adults tested for SARS-CoV-2 at U.S. pharmacies since Sept. 14, bivalent COVID-19 vaccine boosters provided additional protection…
Headline
The Biden Administration today launched a six-week campaign to encourage Americans to get an updated COVID-19 vaccine. In addition to ongoing pop-up clinics,…
Headline
Children under age 5 are more likely to receive a COVID-19 vaccine if their parents perceive it as safe and their health care provider recommends it, according…
Headline
AHA this week released a new Thanksgiving-focused toolkit to help promote pediatric COVID-19 vaccination on social media, including sample content and graphics…
Headline
The Food and Drug Administration recently updated its health care provider fact sheet on bebtelovimab to note that the monoclonal antibody is not expected…
Headline
Black patients who sought outpatient care for COVID-19 between January and July 2022 were 36% less likely than white patients to receive the antiviral pill…